In order to strengthen the expansion of R&D pipelines and accelerate the commercialization of products, strong alliances between pharmaceutical companies have become very common
in the industry in recent years.
Recently, a large number of multinational pharmaceutical companies have released cooperation news
.
On October 19, biopharmaceutical company Jazz Pharmaceuticals and Zymeworks BC, Inc.
, a subsidiary of Zymeworks, announced that they have signed an exclusive license agreement
.
Under the terms of the agreement, Jazz will receive an exclusive license
to develop and commercialize zanidatamab in the United States, Europe, Japan and all locations other than the Asia-Pacific region previously licensed by Zymeworks to BeiGene.
Zymeworks is eligible for an upfront payment of $50 million, plus subsequent payments and various mileage payments, for potential transactions totaling up to $1.
76 billion
.
Zanidatamab is a HER2-targeting bispecific antibody
with a novel mechanism of action.
On October 18, biotech company Ikena Oncology announced that it has entered into a clinical trial cooperation agreement with AstraZeneca to evaluate Tagrisso (osimertinib) and Ikena IK-930 as a treatment for
patients with EGFR-mutated non-small cell lung cancer.
It is understood that ongoing clinical trials will explore different targeted therapy combinations
through a cohort program.
One of the cohorts will focus on the potential of
IK-930 to overcome resistance to EGFR inhibitors.
Preclinical results showed that when IK-930 was used in combination with Tagrisso, it increased the induction of apoptosis and improved anti-tumor activity
in multiple EDGRm tumor models.
On October 17, biotechnology company Kineta, Inc.
announced a collaboration agreement with Merck to combine the investigational antibody KVA12123 with Keytruda (pembrolizumab) as a potential treatment for
advanced solid tumors.
The two companies are expected to initiate clinical trials
later this year.
This trial will evaluate the safety, tolerability, pharmacokinetics, and antitumor response
of KVA12123 alone and in combination with Keytruda.
Top line data
is expected by the end of 2023.
Initial target indications for KVA12123 include non-small cell lung cancer, colorectal cancer, renal cell carcinoma, head, neck, and ovarian cancer
.
Since October, a large number of multinational pharmaceutical companies have also initiated many cooperation
in R&D, promotion and other fields.
In addition to multinational pharmaceutical companies, domestic pharmaceutical companies are increasingly clustered
in innovative drugs.
For example, on October 11, Heyuan Biotechnology (Shanghai) Co.
, Ltd.
officially signed a strategic cooperation agreement
with Shanghai Weimei Gene Technology Co.
, Ltd.
Relying on their own technology accumulation and resource advantages, and with the help of Weimei Gene's AAVmeta vector development platform, the two parties will break the limitations of conventional serotypes in the application of gene therapy, achieve innovative breakthroughs from the underlying technology, and jointly strive to improve the effectiveness, safety and clinical accessibility of gene therapy and accelerate the development of
precision gene therapy.
On October 10, CSPC Group announced that its wholly-owned subsidiary, CSPC Enbip Pharmaceutical Co.
, Ltd.
, entered into an exclusive licensing agreement with Harbour Pharmaceuticals (Shanghai) Co.
, Ltd.
, pursuant to which Embip Pharmaceuticals obtained the exclusive license of Shanghai Platinium Pharmaceuticals to develop, manufacture and commercialize bartolimab
in Greater China.
In consideration of obtaining an exclusive license for the product in the region, Enbip agreed to pay an upfront payment of RMB150 million, up to RMB50 million for potential technology milestones, up to RMB400 million for potential development and regulatory milestones, and up to US$57.
5 million (approximately RMB411 million) for potential sales
milestones.
Enbip also agreed to pay a tiered sales royalty
to Harbour Platinum based on the product's annual net sales in the region.
On the same day, CR Pharma and Fosun Pharma jointly announced a strategic cooperation, under which the two parties will carry out comprehensive cooperation in the field of general health, focusing on innovative drugs, biological drugs, medical devices and other fields through strategic and business cooperation, to strengthen the global layout and industrialization development of both parties in related fields.
.
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
